Endostatin: The logic of antiangiogenic therapy

The Hallmarks of Cancer

2000 • 27,569 citations

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

Tumor Angiogenesis: Therapeutic Implications

1971 • 9,898 citations

Gene expression profiling predicts clinical outcome of breast cancer

2002 • 9,314 citations

Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis

1996 • 6,878 citations

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

2002 • 6,428 citations

Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth

1997 • 4,504 citations

Tumors: Wounds That Do Not Heal

1986 • 4,202 citations

Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk

2003 • 3,381 citations

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1994 • 3,367 citations

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

2004 • 2,481 citations

Epithelial-mesenchymal transition and its implications for fibrosis

2003 • 2,239 citations

Putting tumours in context

2001 • 2,145 citations

Gene-expression profiles predict survival of patients with lung adenocarcinoma

2002 • 2,005 citations

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

2004 • 1,935 citations

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

1997 • 1,705 citations

Clinical translation of angiogenesis inhibitors

2002 • 1,518 citations

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

2000 • 1,310 citations

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1999 • 1,248 citations

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

2004 • 1,231 citations

Targeted cancer therapy

2004 • 1,116 citations

Gene expression-based classification of malignant gliomas correlates better with survival than histological classification.

2003 • 952 citations

Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.

1998 • 887 citations

Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study

2002 • 814 citations

Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us

2002 • 794 citations

Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts

2004 • 733 citations

Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

2002 • 685 citations

Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy.

1999 • 666 citations

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies

2003 • 651 citations

Endostatin Induces Endothelial Cell Apoptosis

1999 • 594 citations

Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection

2003 • 516 citations

Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins

2003 • 473 citations

Secreted cathepsin L generates endostatin from collagen XVIII

2000 • 459 citations

Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding

1999 • 451 citations

Interaction of endostatin with integrins implicated in angiogenesis

2001 • 442 citations

Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

2002 • 427 citations

Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1

2002 • 420 citations

Endostatin's Antiangiogenic Signaling Network

2004 • 397 citations

Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model

2000 • 389 citations

Generation and degradation of human endostatin proteins by various proteinases

2000 • 379 citations

Lack of collagen XVIII/endostatin results in eye abnormalities

2002 • 349 citations

Strategies to overcome resistance to targeted protein kinase inhibitors

2004 • 332 citations

Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis

2005 • 331 citations

Horizontal Transfer of DNA by the Uptake of Apoptotic Bodies

1999 • 318 citations

Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase.

2000 • 316 citations

Cell Surface Glypicans Are Low-Affinity Endostatin Receptors

2001 • 310 citations

The generation of endostatin is mediated by elastase.

1999 • 295 citations

Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors

2002 • 276 citations

Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis

2000 • 273 citations

Chromosome translocations: dangerous liaisons revisited

2001 • 272 citations

Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome)

2000 • 272 citations

Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.

2001 • 259 citations

SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.

2003 • 255 citations

Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily

2002 • 248 citations

Antiangiogenic therapy and tumor progression

2004 • 233 citations

Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors

2003 • 225 citations

Endostatin Causes G1 Arrest of Endothelial Cells through Inhibition of Cyclin D1

2002 • 216 citations

Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin

1999 • 214 citations

Crystal structure of the angiogenesis inhibitor endostatin at 1.5Aresolution

1998 • 209 citations

Antiangiogenesis signals by endostatin

2001 • 198 citations

Cloning, Expression, andin VitroActivity of Human Endostatin

1999 • 188 citations

Cancer: looking outside the genome

2000 • 187 citations

Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors

2005 • 183 citations

Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin

2002 • 182 citations

The antitumoral effect of endostatin and angiostatin is associated with a down‐regulation of vascular endothelial growth factor expression in tumor cells

2002 • 163 citations

Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.

2003 • 163 citations

SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.

2003 • 150 citations

High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours

2001 • 149 citations

Molecular Analysis of Collagen XVIII Reveals Novel Mutations, Presence of a Third Isoform, and Possible Genetic Heterogeneity in Knobloch Syndrome

2002 • 149 citations

Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance

2002 • 145 citations

Minimizing Long-Term Tumor Burden: The Logic for Metronomic Chemotherapeutic Dosing and its Antiangiogenic Basis

2003 • 140 citations

Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis

2000 • 136 citations

Cloning of cDNA and Genomic DNA Encoding Human Type XVIII Collagen and Localization of the α1(XVIII) Collagen Gene to Mouse Chromosome 10 and Human Chromosome 21

1994 • 131 citations

Endostatin regulates endothelial cell adhesion and cytoskeletal organization.

2002 • 125 citations

Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors.

2003 • 124 citations

Endostatin Binds Tropomyosin

2001 • 122 citations

Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity

1998 • 117 citations

Combination Angiostatin and Endostatin Gene Transfer Induces Synergistic Antiangiogenic Activity in Vitro and Antitumor Efficacy in Leukemia and Solid Tumors in Mice

2001 • 116 citations

Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells.

2003 • 113 citations

The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing

2000 • 108 citations

A 27-Amino-Acid Synthetic Peptide Corresponding to the NH2-Terminal Zinc-Binding Domain of Endostatin Is Responsible for Its Antitumor Activity

2005 • 106 citations

In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects

2001 • 106 citations

The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models

2002 • 105 citations

Resistance to imatinib (Glivec): update on clinical mechanisms

2003 • 91 citations

Endostatin regulates branching morphogenesis of renal epithelial cells and ureteric bud

2001 • 90 citations

Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences

2003 • 89 citations

Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.

2001 • 88 citations

Vascular remodeling and clinical resistance to antiangiogenic cancer therapy

2004 • 86 citations

A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma.

2001 • 86 citations

Assessing Tumor Angiogenesis

2004 • 84 citations

Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives

2004 • 82 citations

Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.

2002 • 82 citations

E-selectin is required for the antiangiogenic activity of endostatin

2004 • 82 citations

Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo

2004 • 80 citations

Apoptosis signals in lymphoblasts induced by focused ultrasound

2004 • 65 citations

Increased Angiogenic Response in Aortic Explants of Collagen XVIII/Endostatin-Null Mice

2004 • 62 citations

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer

2005 • 62 citations

Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells

2004 • 60 citations

Setbacks for Endostatin

2002 • 57 citations

The Minimal Active Domain of Endostatin Is a Heparin-Binding Motif that Mediates Inhibition of Tumor Vascularization

2004 • 57 citations

Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro

2003 • 57 citations

Continuous Intravascular Secretion of Endostatin in Mice from Transduced Hematopoietic Stem Cells

2002 • 56 citations

Stimulation and Inhibition of Angiogenesis in Diabetic Retinopathy

2001 • 49 citations

Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system.

2003 • 42 citations

Early Genetic Mechanisms Underlying the Inhibitory Effects of Endostatin and Fumagillin on Human Endothelial Cells

2004 • 42 citations

Variable zinc coordination in endostatin

2000 • 36 citations

Endostatin's endpoints—Deciphering the endostatin antiangiogenic pathway

2004 • 30 citations

19 The Logic of Anti-angiogenic Gene Therapy

1999 • 26 citations

Multidrug resistance‐1 (MDR‐1): a new target for T cell‐based immunotherapy

2004 • 25 citations

Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay.

2003 • 25 citations

Cellular Actions and Signaling by Endostatin

2002 • 23 citations

Do antiangiogenic protein fragments have amyloid properties?

2004 • 23 citations

Antiangiogenic Therapy and p53

2002 • 19 citations

Genome Wide Expression Profiling of Angiogenic Signaling and the Heisenberg Uncertainty Principle

2004 • 7 citations